Engimmune Therapeutics raises CHF 15.5m in Seed Financing
4 May 2022 – Walder Wyss advises Engimmune Therapeutics in connection with the CHF 15.5m seed financing round co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch.
Engimmune Therapeutics is a platform company using cutting-edge technologies to engineer highly potent and specific TCR-based therapies for cancer treatment.
Proceeds from the financing will be used to further build Engimmune Therapeutics’ pipeline, expand the research team in Switzerland and build a foothold in Denmark, with a focus on GMP-certified manufacturing, clinical development, and regulatory affairs.
The Walder Wyss team includes Alexander Gutmans (Partner, Corporate/M&A and Venture Capital), Karina Tschon (Associate, Corporate/M&A and Venture Capital), Lena Götzinger (Associate IP/Licensing), Lucas Maurer (Associate, Corporate/M&A and Venture Capital) and Michelle Bruni (Senior Associate, Corporate/M&A and Tax).